Poster Sessions will be held on site and virtually.

**Poster Session 1**
Wednesday, December 8 7:00 am – 8:30 am CST

- **Palbociclib**
  - **Poster Spotlight Session 1**
    - Feasibility of palbociclib in women aged 70 and older with advanced breast cancer pretreated with systemic treatment in PALOMAGE study
    - View Presentation
  - **Poster Session 1**
    - P1-18-04
      - Palbociclib
    - Preclinical characterization of palbociclib plus letrozole or letrozole-alone for metastatic breast cancer patients with lung metastases: fictional database analysis
    - View Presentation
    - P1-18-05
      - Palbociclib
    - Early changes in circulating tumor DNA (ctDNA) and impact on clinical outcomes associated with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS
    - View Presentation
    - P1-18-13
      - Palbociclib
    - Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2–): ABC
    - View Presentation
    - P1-18-20
      - Palbociclib
    - Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung/liver metastases: Flatiron database analysis
    - View Presentation
    - P1-18-25
      - Palbociclib
    - Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study
    - View Presentation
  - **Poster Spotlight Session 2**
    - Impact of using cross-platform gene expression profiling technologies and computational methods for its primary breast cancer subtype in PALOMA-2 and PALLET
    - Cheang M
    - View Presentation

**Poster Session 2**
Wednesday, December 8 5:00 pm – 6:30 pm CST

- **Talazoparib**
  - **Poster Session 2**
    - P2-09-05
      - Talazoparib
    - Germline BRCA1/2 mutation testing in human epidermal growth factor receptor 2-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)
    - Niyazov A
    - View Presentation
    - P2-09-08
      - Talazoparib
    - Impact of race on clinical outcomes among patients (pts) with HER2– advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study
    - Whitaker K
    - View Presentation
  - **Ongoing Trials Poster Session 2**
    - Thursday, December 9 5:00 pm – 6:30 pm CST
    - Palbociclib
      - OT2-19-04
        - European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world noninterventional study (EUCHARIS)
        - Law E
        - View Presentation
  - **Poster Session 5**
    - Friday, December 10 7:00 am – 8:30 am CST
    - **Talazoparib**
      - P5-14-08
        - Rugo HS
        - Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study
        - View Presentation
    - **CDK346**
      - P5-16-06
        - A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer
        - Yap TA
        - View Presentation
  - **Poster Spotlight Session 13**
    - Friday, December 10 7:00 am – 8:30 am CST
    - **ARV-471**
      - PD-13-08
        - First in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2– locally advanced or metastatic breast cancer
        - Hamilton E
        - View Presentation

**San Antonio Breast Cancer Symposium**
San Antonio, TX, USA and Virtual
December 7-10, 2021

View additional Pfizer congress materials:
PM Congress Portal